Hyperkalaemic muscle paresis - Side-effect of prostaglandin inhibition in a haemodialysis patient

Nephrology Dialysis Transplantation

Volumn 14, Issue 2, 1999, Pages 480-482

  Nielsen, Eigil Husted ^a  

^a NONE   (Denmark)

Author keywords

Adverse NSAID reaction; Diabetes mellitus; Haemodialysis; Hyperkalaemia; Nephrosis; Paralysis; Tolfenamic acid

Indexed keywords

ANALGESIC AGENT; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLUCOSE; INSULIN; POTASSIUM ION; PROSTAGLANDIN INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DIABETIC NEPHROPATHY; HEMODIALYSIS; HUMAN; HYPERKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE STRENGTH; NEPHROTIC SYNDROME; PARESIS; PRIORITY JOURNAL;

ADULT; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETIC NEPHROPATHIES; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MALE; MUSCULAR DISEASES; NEPHROTIC SYNDROME; PARALYSIS; PROSTAGLANDIN ANTAGONISTS; RENAL DIALYSIS;

EID: 0032917521     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.2.480     Document Type: Article

References (10)

1. Pedersen SB. Biopharmaceutical aspects of tolfenamic acid. Pharmacol Toxicol Suppl 1994; 75 [Suppl II]: 22-32
2. Verbeeck RK. Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs. J Rheumatol 1988; 15 [Suppl 17]: 44-57
3. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol 1995; 4: 1134-1142
4. Láznicek M, Senius KEO. Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease. Eur J Clin Pharmacol 1986; 30: 591-596
5. Brater DC. Drug drug and drug disease interactions with non-steroidal anti-inflammatory drugs. Am J Med 1986; 80 [Suppl 1A]: 62-75
6. Henry DA. Side effects of non-steroidal anti-inflammatory drugs. Bailliere's Clin Rheumatol 1988; 2: 425-454
7. Freeman SJ, Fale AD. Muscular paralysis and ventilatory failure caused by hyperkalemia. Br J Anaesth 1993; 70: 226-227
8. Brady HR, Goldberg H, Lunski C, Uldall PR. Dialysis-induced hyperkalemia presenting as profound muscle weakness. Int J Artif Organs 1988; 11: 43-44
9. Schlueter W, Keilani T, Battle DC. Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors. Am J Med Sci 1994; 307: S81-86
10. Boero R, Guarena C, Berto IM et al. Erythrocyte Na,K pump activity and arterial hypertension in uremic dialyzed patients. Kidney Int 1988; 34: 691-696